Insights from 2023 ASH Annual Meeting
Avatar

ASH 2023 Insights: "Impact of Dex Dose Strength on Outcomes in NDMM"

By Insights from 2023 ASH Annual Meeting FEATURING Rahul Banerjee
By Insights from 2023 ASH Annual Meeting FEATURING Rahul Banerjee
0 views
December 29, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Recommended

AUTOPLAY
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
12:33
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…

Feat. K. Patel
23:09
5th SOHO Italy Annual Conference

SOHO Italy 2023: Is Anti-CD38-Based Induction Therapy for Every Pati…

Feat. P. Richardson
28:11
Total Health

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Feat. M. Rotta
06:11
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…

Feat. A. Varshavsky-Yanovsky
30:18
UChicago Medicine

Practice-Changing and Promising New Treatments in Myeloma

Feat. B. Derman
41:52
MyCancerHaven

How I Approach Frontline Treatment for Patients With MM

Feat. R. Vij, S. Goyal
25:36
MyCancerHaven

Experts Discuss the Bispecific Antibody Talquetamab in Patients With…

Feat. R. Vij, G. Kaur
08:48
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Isa-KRd in High-Risk NDMM - Planned Interim…

Feat. L. Leypoldt
31:27
MyCancerHaven

Experts Discuss the Initial Treatment and Monitoring in Multiple Mye…

Feat. R. Vij, A. Nooka
10:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Feat. T. Martin
35:24
Louisville Hematology Highlights

Is a Bigger Induction "Hammer" Necessarily Better in Today…

Feat. W. Tse
45:43
MedNews Week

Multiple Myeloma in 2022: Developments, Directions, and Disparities

Feat. J. Mikhael
15:34
MyCancerHaven

Experts Discuss the Use of Monoclonal Antibodies in MM

Feat. R. Vij, S. Goldsmith
14:20
MyCancerHaven

Overview of Proteasome Inhibitors in MM: Bortezomib, Carfilzomib &am…

Feat. R. Vij, S. Ailawadhi
09:57
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KRd vs. Elotuzumab + KRd in Transplant-El…

Feat. S. Knop
44:44
University of Colorado Division of Hematology

Drug-Resistant Subpopulations in Patients With Multiple Myeloma

Feat. D. Sherbenou
11:54
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Manage Transplant-Eligible Frontline Multiple…

Feat. V. Montefusco
15:39
5th SOHO Italy Annual Conference

SOHO Italy 2023: MRD by NGS in MM

Feat. K. Ramasamy
14:51
Larry Anderson

Multiple Myeloma: Frontline Therapy Updates